Sagimet Biosciences Inc (SGMT) is heading in the right direction with an average volume of $1.75M

Sagimet Biosciences Inc (NASDAQ: SGMT) started the day on Wednesday, with a price increase of 3.63% at $5.43, before settling in for the price of $5.24 at the close. Taking a more long-term approach, SGMT posted a 52-week range of $2.13-$20.71.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


It was noted that the giant of the Healthcare sector posted annual sales growth of 0.00% over the last 5 years. Meanwhile, its Annual Earning per share during the time was -16.23%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 22.63%. This publicly-traded company’s shares outstanding now amounts to $21.38 million, simultaneously with a float of $12.11 million. The organization now has a market capitalization sitting at $124.35 million. At the time of writing, stock’s 50-day Moving Average stood at $7.15.

Sagimet Biosciences Inc (SGMT) Ownership Facts and Figures

Now let’s turn our focus to how large-scale investors are working with this stock of the Biotechnology Industry. Sagimet Biosciences Inc’s current insider ownership accounts for 47.10%, in contrast to 53.11% institutional ownership. According to the most recent insider trade that took place on Mar 26 ’24, this organization’s President & CEO bought 12,100 shares at the rate of 5.27, making the entire transaction reach 63,731 in total value, affecting insider ownership by 639,200. Preceding that transaction, on Dec 07 ’23, Company’s President & CEO bought 1,600 for 4.10, making the whole transaction’s value amount to 6,560. This particular insider is now the holder of 627,100 in total.

Sagimet Biosciences Inc (SGMT) Earnings and Revenue Records

In the latest quarterly report released, which was put into the public domain on 12/30/2023, the organization reported -$0.78 earnings per share (EPS) for the three months, lower than the consensus estimate (set at -$0.58) by -$0.2. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.42 per share during the current fiscal year.

Sagimet Biosciences Inc’s EPS increase for this current 12-month fiscal period is 22.63% and is forecasted to reach -3.49 in the upcoming year.

Sagimet Biosciences Inc (NASDAQ: SGMT) Trading Performance Indicators

Let’s observe the current performance indicators for Sagimet Biosciences Inc (SGMT). It’s Quick Ratio in the last reported quarter now stands at 17.04. The Stock has managed to achieve an average true range (ATR) of 0.75. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 62.17.

In the same vein, SGMT’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.28, a figure that is expected to reach -0.40 in the next quarter, and analysts are predicting that it will be -3.49 at the market close of one year from today.

Technical Analysis of Sagimet Biosciences Inc (SGMT)

If we take a close look at the recent performances of Sagimet Biosciences Inc (NASDAQ: SGMT), its last 5-days Average volume was 0.86 million that shows plunge from its year to date volume of 1.71 million. During the previous 9 days, stock’s Stochastic %D was recorded 57.97% While, its Average True Range was 0.66.

Raw Stochastic average of Sagimet Biosciences Inc (SGMT) in the period of the previous 100 days is set at 17.76%, which indicates a major fall in contrast to 71.49% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 100.99% that was lower than 225.70% volatility it exhibited in the past 100-days period.